Cancer biology and oncology
4 European H2020 organizations list this as part of their work — 3 as their primary capability.
Most active in this area
- INSTITUT CURIE
Leading French cancer research centre combining clinical oncology with fundamental epigenetics, genomics, and cell biology across 83 H2020 projects.
“Core theme across projects including UM Cure 2020 (uveal melanoma therapy), BRIDGES (breast cancer genetic risk), ITCC-P4 (pediatric cancer), FiBRO (rectal cancer), and INTEGRISTEM (mammary tumorigenesis).”
PrimaryFR83 projects - ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM
Amsterdam's leading academic medical center with deep H2020 expertise in immunology, cardiovascular research, infectious disease, and in silico clinical trials.
“Coordinated CRCStemCellDynamics (colorectal cancer stem cells) and CTC4BMP (circulating tumor cells), plus participation in META-CAN and GlySign (glycosylation in precision medicine).”
NL51 projects - FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE
Barcelona-area biomedical research institute specializing in cancer biology, vascular stem cells, iPSC disease modeling, and 3D tissue engineering.
“Dominant theme across projects including EPICUP, EPIPHARM (cancer diagnostics via DNA methylation), META-CAN (cancer metabolism), Evomet (metastasis evolution), PLEIO-RANK (cancer stem cells), and Organ-VIP (colorectal cancer organoids).”
PrimaryES24 projects - HARVARD GLOBAL RESEARCH AND SUPPORT SERVICES INC.
Harvard University's administrative entity for EU research partnerships, contributing specialist faculty expertise across cancer biology, physics, and humanities.
“B-CAST focused on breast cancer molecular subtypes and risk stratification; KILL-OR-DIFFERENTIAT investigates neural crest tumors including neuroblastoma and pheochromocytoma; COSMIC studied malaria parasite biology.”
PrimaryUS7 projects